Plain-English translation of NCT04467723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding pirfenidone to (a medication already used to treat advanced lung cancer) can help fight the cancer better and prevent it from becoming resistant to treatment. You would receive both medications together: as an IV infusion every three weeks, and pirfenidone as pills you take by mouth three times daily. The study wants to see if this combination is more effective than alone.
Some lung cancers stop responding to current immunotherapy treatments over time. Researchers believe that adding this medication might help prevent resistance and make the treatment work better for patients whose cancer has already progressed despite previous therapies.
You likely qualify if…
You likely don't qualify if…
You would receive as an intravenous infusion on day 1, then every three weeks throughout the study. At the same time, you would start taking pirfenidone pills by mouth with food—beginning with a lower dose and gradually increasing it over the first month until you reach the full daily dose. You would continue both medications until your cancer progresses or you experience unacceptable side effects. You will have regular doctor visits, blood tests, and imaging scans to monitor how you are responding to treatment and to check for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
University of Kansas Medical Center
Collaborators
parkview cancer institute
Enrollment target
~25 participants
Started
May 2022
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
KUCC Navigator
The University of Kansas
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.